X4 Pharmaceuticals names Sudha Parasuraman as chief medical officer
Dr. Parasuraman is a board-certified hematologist and oncologist with a strong clinical background and deep experience in all phases of oncology drug development.
Dr. Parasuraman brings more than 15 years of industry, academic and community practice experience in hematology, oncology, and pediatrics to drug development.
Most recently she served as Vice President, Global Medical Affairs at uniQure Inc, where she worked on gene therapies for rare diseases.
Prior to uniQure, she held senior medical positions at Novartis, where she led the early development program for the CDK4/6 inhibitor, ribociclib, and was instrumental in paving the path for accelerated registration studies.
She went on to provide medical leadership for a series of innovative clinical trials in the Signature Program and the commercial strategies for early-stage compounds in the portfolio.
Dr. Parasuraman also served as Medical Director at Millennium Pharmaceuticals (now Takeda Oncology) where she was the medical lead for several programs including the clinical development and lifecycle management of the first-in-class cancer therapy, Velcade.
Previously, Dr. Parasuraman was a faculty member at Harvard Medical School and was staff physician at Children’s Hospital of Boston, Dana Farber Cancer Institute, and Brigham and Women’s Hospital.
Dr. Parasuraman completed her fellowship in pediatric hematology-oncology at St. Jude Children’s Research Hospital in Memphis, TN and pediatric residencies at Children’s Hospital of Michigan and Los Angeles County/University of Southern California Medical Center.
She received her medical degree from the University of Madras, India. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
JD Wetherspoon FY17 profit climbs Earnings
Sinopec's net profit surges 40% Earnings